Critical appraisal of the private genetic and pharmacogenomic testing environment in Greece

Personalized Medicine

Volumn 8, Issue 4, 2011, Pages 413-420

  Sagia, Aggeliki ^a   Cooper, David N ^b   Poulas, Konstantinos ^a   Stathakopoulos, Vlassios ^c   Patrinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ATHENS UNIVERSITY OF ECONOMICS AND BUSINESS   (Greece)

Author keywords

cytogenetics; genetic testing; Greece; molecular genetics; pharmacogenomics; physicians; private laboratories

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; CYTOGENETICS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GREECE; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL;

EID: 79960947911     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.24     Document Type: Article

References (15)

1. Chen JM, Férec C, Cooper DN. Revealing the human mutome. Clin. Genet. 78(4), 310-320 (2010).
2. Cooper DN, Chen JM, Ball EV et al. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum. Mutat. 31(6), 631-655 (2010).
3. Metzker ML. Sequencing technologies - the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010).
4. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277-287 (2009).
5. Caulfield T, Ries NM, Ray PN, Shuman C, Wilson B. Direct-to-consumer genetic testing: good, bad or benign? Clin. Genet. 77(2), 101-105 (2010).
6. Davies K. The $1000 Genome. The Revolution in DNA Sequencing and the New Era of Personalized Medicine. Free Press, NY, USA (2010).
7. Burnett D. Quality control in the genetic laboratory. In Molecular Diagnostics, 2nd Edition. Patrinos GP, Ansorge W (Eds).Elsevier/Academic Press, Burlington, MA, USA (2009).
8. Gurwitz D, Bregman-Eschet Y. Personal genomics services: whose genomes? Eur. J. Hum. Genet. 17(7), 883-889 (2009).
9. Guttmacher AE, McGuire AL, Ponder B, Stefánsson K. Personalized genomic information: preparing for the future of genetic medicine. Nat. Rev. Genet. 11(2), 161-165 (2010).
10. Mai Y, Koromila T, Sagia A et al. A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genetic testing in Greece. Pers. Med. (2011) (In Press).
11. Grimaldi KA, Look MP, Scioli GA, Clavero JC, Marinos S, Tagaris T. Personal genetics: regulatory framework in Europe from a service provider's perspective. Eur. J. Hum. Genet. 19(4), 382-388 (2011).
12. Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Ann. Rev. Genomics Hum. Genet. 9, 161-182 (2008).
13. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition).Chest 133(Suppl. 6), 160S-198S (2008). (Pubitemid 351892967)
14. Kricka LJ, Fortima P, Mai Y, Patrinos GP. Direct-access genetic testing: the view from Europe. Nat. Rev. Genet. (2011) (In Press).
15. Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE. Quality control in molecular genetic testing. Nat. Rev. Genet. 2(9), 717-723 (2001). (Pubitemid 33674793)